GETTING BETTER SOONER
Pending · Published for Opposition LIVE/APPLICATION/Published for Opposition
What this record means
The record shows a live, pending application for the mark “GETTING BETTER SOONER” owned by Annexon, Inc., a Delaware corporation, and it is currently published for opposition as of November 10, 2026. The goods and services listed fall in three classes: Class 005 covers pharmaceutical preparations for treating a wide range of immune‑system, neurological, ophthalmic and other serious diseases; Class 042 includes pharmaceutical research and development, consulting, and the provision of medical and scientific research information; and Class 044 limits the mark to providing medical information related to pharmaceuticals. Because the listed scope is centered on high‑tech medical and pharmaceutical activities, a similar name used in those same fields would present the closest record‑based concern, while uses outside those areas are farther from the specific scope shown. The latest meaningful event is the publication for opposition on November 10, 2026, and the supplied history shows no oppositions, cancellations or other enforcement actions. I'd treat this as a meaningful concern if you plan to use the phrase in any pharmaceutical or medical‑research context.
Informational only - not legal advice.Mark Trademark, Service Mark
| Drawing type | 4 - STANDARD CHARACTER MARK |
| Filing basis | Intent-to-Use (§1(b)). |
| Status | Application has been published for opposition. The opposition period begins on the date of publication. |
Key dates
| Application filed | Aug 12, 2024 |
| Published for opposition | Nov 10, 2026 |
| Status date | Nov 10, 2026 |
Goods & services
Pharmaceutical preparations for the treatment of immune system related diseases and disorders, complement-mediated diseases and disorders, neurological diseases and disorders, and ophthalmic diseases and disorders; pharmaceutical preparations for the treatment of Guillain-Barré syndrome, macular degeneration, geographic atrophy, Huntington's Disease, amyotrophic lateral sclerosis (ALS), lupus, cold agglutinin disease (CAD), chronic inflammatory demyelinating polyneuropathy (CIDP), and myasthenia gravis (MG)
Pharmaceutical research and development; consulting services in the field of pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials
Providing medical information; providing medical information related to pharmaceuticals
Madrid Protocol · §66(a)
| Intl. registration no. | 1831018 |
Owner & representation
| Owner | Annexon, Inc. |
| Address | 1400 Sierra Point Pkwy., Bldg. C, 2nd Fl, Brisbane, CALIFORNIA UNITED STATES 94005 |
| Entity | CORPORATION - organized in DELAWARE |
| Attorney of record | Joshua S. Jarvis, Esq. |
| Correspondent | Joshua S. Jarvis, Esq. |
| Attorney email | u********@*****.com |
| Correspondent email | 2 emails |
| Correspondent phone | 6********0 |
| Correspondent address | Boston, MASSACHUSETTS |